Downloads

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve preclinical/clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The company has an exclusive collaboration and license agreement with Spark Therapeutics for the CG01 project and a collaboration agreement with the Danish company Zyneyro within the pain program COZY.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market.

Logotype – CMYK

(Vector graphic PDF file)

CombiGene logo - CMYK

CombiGene logo neg - CMYK

CombiGene logo green figure neg - CMYK

Logotype – sRGB

(screen graphics)

CombiGene logo - sRGB

CombiGene logo neg - sRGB

CombiGene logo green figure neg - sRGB

About CombiGene AB

Follow what's happening at CombiGene, subscribe to our newsletter.